ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2018
Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges.Heart failure reviews · 2021Pooled it
- Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Pooled it
- Update of the Brazilian Guideline on Nuclear Cardiology - 2020.Arquivos brasileiros de cardiologia · 2020Guideline
- Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.European journal of nuclear medicine and molecular imaging · 2018Pooled it
- Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis.European heart journal. Imaging methods and practice · 2026Article
- Cardiac phenotype in hereditary transthyretin amyloidosis: correlations between fibril types and 99mTc-DPD uptake.Scientific reports · 2026Article
- Invasive pressure-volume loop and PET-MR phenotyping in transthyretin cardiac amyloidosis: a multimodal imaging case report.European heart journal. Case reports · 2026Article
- Pittsburgh compound B positron emission tomography detects cardiomyopathy in hereditary transthyretin amyloidosis patients with negative bone scintigraphy: a pilot study.Frontiers in nuclear medicine · 2026Article
- Total-body positron emission tomography: Investigating mechanisms in cardiovascular-kidney-metabolic syndrome.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Review
- Recent Advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis.Current cardiology reports · 2024Review
- Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- The clinical value of quantitative cardiovascular molecular imaging: a step towards precision medicine.The British journal of radiology · 2023Review
- Value of nuclide scintigraphy in the diagnosis and prognosis of cardiac amyloidosis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Clinical considerations in early-onset cerebral amyloid angiopathy.Brain : a journal of neurology · 2023Review
- LV functional evaluation onJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.Acta Cardiologica Sinica · 2023Article
- The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDPD scintigraphy has been advocated for imaging cardiac amyloid in ATTR amyloidosis. PET utilizing
methodsTen patients with biopsy-proven V30M ATTR amyloidosis and discrete or no signs of cardiac involvement were included. Patients were grouped according to TTR-fragmentation. All underwent DPD scintigraphy, echocardiography, and PIB-PET. A left ventricular PIB-retention index (PIB-RI) was established and compared to five normal volunteers.
resultsPIB-RI was increased in all patients (P < 0.001), but was significantly higher in type B than in type A (0.129 ± 0.041 vs 0.040 ± 0.006 min
conclusionPIB-PET, in contrast to DPD scintigraphy, has the potential to specifically identify cardiac amyloid depositions irrespective of amyloid fibril composition. The heart appears to be a target organ for amyloid deposition in ATTR amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.